PARP1 and neuroblastoma: We hypothesized that the BET inhibitor JQ1 would promote a DNA repair-deficient phenotype, sensitizing NB cells to PARP inhibition by Olaparib, and sought to determine how MYCN amplification status may affect the efficacy of this combination therapy.